Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration

This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.

FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS^® Registry.

Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01).

Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-naïve eyes experienced anatomical improvement.